These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 29742274

  • 41. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
    Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K, PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators.
    Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
    [Abstract] [Full Text] [Related]

  • 42. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H.
    J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
    [Abstract] [Full Text] [Related]

  • 43. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.
    Farhi D.
    Drugs Today (Barc); 2010 Apr; 46(4):259-64. PubMed ID: 20502723
    [Abstract] [Full Text] [Related]

  • 44. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.
    Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B.
    Br J Dermatol; 2017 Dec; 177(6):1537-1551. PubMed ID: 28600810
    [Abstract] [Full Text] [Related]

  • 45. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, Day RM, Chen R, Shah K, Ferrándiz C, Cather JC.
    J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
    [Abstract] [Full Text] [Related]

  • 46. A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab.
    Du Jardin KG, Hurtado Lopez P, Lange M, McCool R, Maeso Naval S, Quickert S.
    J Health Econ Outcomes Res; 2020 Aug; 7(2):123-129. PubMed ID: 32766377
    [Abstract] [Full Text] [Related]

  • 47. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
    Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB, PHOENIX 1, PHOENIX 2, and ACCEPT investigators.
    J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
    [Abstract] [Full Text] [Related]

  • 48. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 49. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Li W, Ghamrawi R, Haidari W, Feldman SR.
    Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
    [Abstract] [Full Text] [Related]

  • 50. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K.
    J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
    [Abstract] [Full Text] [Related]

  • 51. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
    Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, Li J, Baumgartner SW.
    J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Tildrakizumab: First Global Approval.
    Markham A.
    Drugs; 2018 Jun; 78(8):845-849. PubMed ID: 29752706
    [Abstract] [Full Text] [Related]

  • 58. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.
    Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW.
    J Am Acad Dermatol; 2021 Sep; 85(3):572-581. PubMed ID: 33631216
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A, Papavassilis C, Bhosekar V, Reinhardt M.
    Drugs Aging; 2018 Feb; 35(2):135-144. PubMed ID: 29404966
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.